ART3

ART3 is a cell-surface ADP-ribosyltransferase implicated in promoting tumor cell growth: its overexpression in triple-negative breast cancer cells drives proliferation, invasion, and survival in vitro and xenograft tumor growth, with concomitant activation of the AKT and ERK signaling pathways, while its knockdown suppresses proliferation and invasion (PMID:27374177). The human gene is controlled by two alternative promoters with tissue-preferential usage and produces multiple splice variants distinguished by inclusion or exclusion of exon 2, which encodes most of the ART3 protein, a regulatory architecture conserved between human and mouse (PMID:16934346). Beyond these observations, the direct enzymatic substrates of ART3 and the mechanism linking it to AKT/ERK activation have not been characterized in the available corpus.

1. 2006 Medium

   Established how ART3 expression is genetically organized, showing that alternative promoter usage and exon 2-dependent splicing generate tissue-preferential ART3 isoforms.

   Evidence RT-PCR across multiple tissues, sequence alignment with genomic clone, and 5' UTR characterization in human and mouse

   PMID:16934346

   Open questions at the time

   • Does not define the function or enzymatic competence of the individual splice isoforms
   • Does not link any promoter/isoform to a specific physiological or disease context
   • No protein-level confirmation of the predicted isoforms
2. 2016 Medium

   Tested whether ART3 has a functional role in cancer, demonstrating that it promotes breast cancer cell proliferation, invasion, and survival via AKT and ERK pathway activation.

   Evidence Gain- and loss-of-function (overexpression and knockdown) in MDA-MB-231 cells, xenograft tumor growth, and immunoblotting for AKT/ERK

   PMID:27374177

   Open questions at the time

   • Does not identify the ADP-ribosylation substrate(s) responsible for the phenotype
   • Mechanism connecting ART3 enzymatic activity to AKT/ERK activation is undefined
   • Single cell line and single lab; generality across cancer types untested

• The direct enzymatic substrates of ART3 and the molecular mechanism coupling its activity to downstream signaling remain unidentified.
• No substrate of ART3 ADP-ribosyltransferase activity has been defined in the corpus
• No structural or biochemical reconstitution of catalytic activity
• Mechanistic basis of AKT/ERK activation unresolved